Clinical Trial Update: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updating on the use of entospletinib with obinutuzumab in relapsed CLL/SLL or NHL; Phase 1/2 study status completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Entospletinib (entospletinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Alexey Danilov, MD | Conditions: Anemia, B-Cell Prolymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-08